AI assistant

Sign in to chat with this filing

The assistant answers questions, extracts KPIs, and summarises risk factors directly from the filing text.

Sign up Log in

Biohit Oyj Board/Management Information 2022

Sep 2, 2022

3304_iss_2022-09-02_12ec642c-02b3-4891-8868-f17681f8099a.pdf

Board/Management Information

Open in viewer

Opens in your device viewer

Change of CEO at Biohit Oyj

Publishing on September 2, 2022 at 12:00 am local time (EEST)

CEO Päivi Siltala has resigned. The Board of Directors of Biohit Oyj has appointed CFO Jussi Hahtela the new CEO. Hahtela will start in the new role immediately.

Chairperson of the Board of Directors, PhD Lea Paloheimo: "Hahtela has as the CFO had an important role in business development and improved profitability. The Board of Directors believe that CEO change will strengthen the positive development further."

Master of Social Sciences Jussi Hahtela (b. 1973) has worked at Biohit as CFO from June 2021. He has previously worked in Nordea for example as chief strategist and Head of FX sales Finland.

Additional information:

[email protected] www.biohithealthcare.com

Biohit in brief

Biohit Oyj is a globally operating Finnish biotechnology company. Biohit mission is "Innovating for Health" – we produce innovative products and services to promote research and early diagnosis. Biohit is headquartered in Helsinki, Finland, and has subsidiaries in Italy and the UK. Biohit Series B share (BIOBV) is quoted on Nasdaq Helsinki in the Small cap/Healthcare group. www.biohithealthcare.com